Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | SLC2A9 | Q9NRM0 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338328 | 1.00 | KIF11 (0.36) | KIF11CYP3A4ALOX15CYP2D6SIRT2 | |
| SCHEMBL28908862 | 0.85 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL28908721 | 0.82 | SLC6A3 (0.39) | KIF11KMT2APDE5A | |
| SCHEMBL13937363 | 0.82 | ACHE (0.44) | KMT2AMEN1MAPT | |
| SCHEMBL25815905 | 0.82 | MAPT (0.33) | KIF11KMT2AMEN1PDE5AALDH1A1 | |
| SCHEMBL30337762 | 0.82 | MAPT (0.33) | KIF11KMT2AMEN1PDE5AALDH1A1 | |
| SCHEMBL25816150 | 0.82 | MAPT (0.33) | KIF11KMT2AMEN1PDE5AALDH1A1 | |
| SCHEMBL30356308 | 0.81 | KIF11 (0.39) | KIF11SIRT2SLC22A12SLC2A9ALDH1A1 | |
| SCHEMBL25815906 | 0.81 | KIF11 (0.39) | KIF11SIRT2SLC22A12SLC2A9ALDH1A1 | |
| SCHEMBL30967887 | 0.77 | ACHE (0.41) | KIF11KMT2AMEN1PDE5AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448363-B2 | Kinase inhibitors | VIDYA THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4157446-A1 | KINASE INHIBITORS | GB002, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-115867346-A | Kinase inhibitors | GB005股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448363-B2 | Kinase inhibitors | BTK, ABL1, LYN | KIF11 3743/4885CYP3A4 3687/4885ALOX15 4113/4885 |
| US-20230219923-A1 | KINASE INHIBITORS | BTK, ABL1, LYN | KIF11 3743/4885CYP3A4 3687/4885ALOX15 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.